USFDA gives Aurobindo Pharma's Apitoria unit VAI status
In short
The US FDA inspected Aurobindo Pharma’s Unit-VI facility in E-Bonangi village, Anakapalli district, from August 24 to August 28, 2026. The site was given a “voluntary action indicated” classification.
What the reporting says
The US FDA inspected Aurobindo Pharma’s Unit-VI facility at E-Bonangi village in Anakapalli district between August 24 and August 28, 2026. The inspection led to a “voluntary action indicated” classification for the site. The update is relevant for the company because US FDA inspection outcomes can affect regulatory oversight and future US market operations.
Why it matters
Aurobindo Pharma’s Unit-VI facility in E-Bonangi village, Anakapalli district, was inspected by the US FDA from August 24 to August 28, 2026, and received a voluntary action indicated classification. The finding points to regulatory attention at the plant and is relevant to the company’s compliance profile.